View Older Stories View More Recent Stories

May 20, 2022 09:20AM Atara Biotherapeutics (ATRA) PT Lowered to $16 at Stifel on Bayer Deal Pull Out, Reiterates Focus on ATA188
May 20, 2022 06:04AM Sanara MedTech (SMTI) PT Lowered to $40 at Cantor Fitzgerald, Overweight Rating Maintained
May 19, 2022 12:36PM "We Think There is a Good Chance of Broad-label Approval" - Needham & Company Bullish on Zealand Pharma (ZEAL) Following Phase 3 Data
May 19, 2022 08:20AM Dawson James Reiterates Neutral Rating on Adamis Pharmaceuticals (ADMP)
May 19, 2022 08:09AM Dawson James Reiterates Buy Rating, $5 Price Target on Genius Brands (GNUS) on Marvel Studios Deal
May 19, 2022 06:33AM "Shares Hold Significant Upside Potential" - Oppenheimer Reiterates Outperform Rating, $5 Price Target on Avalo Therapeutics (AVTX)
May 18, 2022 06:10PM Cantor Fitzgerald Reiterates Overweight Rating, $53 Price Target on Insmed (INSM)
May 18, 2022 09:37AM Allakos Inc. (ALLK) PT Lowered to $10 at Cantor Fitzgerald, But BUY Rating Maintained, "Still Believe that the Market Opportunity for lirentelimab is Underappreciated"
May 18, 2022 09:33AM Bass Pro Shops and Cabela’s Deal is "Very Good News" - Dawson James Reiterates Byrna Technologies (BYRN) at Buy with $12 Price Target
May 18, 2022 06:17AM Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX), Has a "More Favorable View of the Company"
May 18, 2022 06:13AM Cantor Fitzgerald Reiterates Overweight Rating, $19 Price Target on Exagen (XGN) on Alivio Health Agreement
May 18, 2022 06:11AM H.C. Wainwright Reiterates Maintains Galmed Pharmaceuticals (GLMD) at Neutral on Aramchol Uncertainties
May 18, 2022 06:10AM "Spikevax/Booster Sales Expectations are Largely Reflected in the Stock" - Needham & Company Maintains Moderna (MRNA) at Hold
May 18, 2022 06:08AM H.C. Wainwright Reiterates Buy Rating, $7 Price Target on VYNE Therapeutics (VYNE)
May 18, 2022 05:59AM Brookline Capital Markets Reiterates Moderna (MRNA) at Buy, "Platform Power Gets More and More Impressive"
May 17, 2022 11:03AM Mizuho Securities Reiterates ContraFect (CFRX) a Buy with $9 Price Target Ahead of Upcoming DISRUPT Study Readout
May 17, 2022 10:40AM Avrobio (AVRO) PT Lowered to $6 at Needham & Company, "Buy" Rating Maintained, "Encouraged by Evolving ARV-RD-04 Results"
May 17, 2022 08:23AM Celcuity Inc (CELC) PT Lowered to $25 at Needham & Company
May 17, 2022 06:48AM Cantor Fitzgerald Reiterates Neutral Rating on TherapeuticsMD (TXMD)
May 17, 2022 06:46AM Stifel Reiterates Hold Rating on Homology Medicines (FIXX)
May 17, 2022 06:44AM Oppenheimer Reiterates Outperform Rating, $9 Price Target on Syros Pharmaceuticals (SYRS), "Investors Can Look Forward to Multiple Catalysts"
May 17, 2022 06:39AM Clarus (CRXT) PT Slashed to $3 at Needham & Company on "Significant Financing Overhang"
May 17, 2022 06:13AM UPDATE: Aytu Biosciences (AYTU) PT Lowered to $5 at Cantor Fitzgerald, "Overweight" Rating Reiterated, Analyst Expects "Upwards Earnings Revisions Should Drive Shares Higher"
May 17, 2022 06:13AM Spero Therapeutics (SPRO) PT Slashed to $5 at Cantor Fitzgerald, Analyst Maintains "Overweight" Rating
May 17, 2022 06:08AM Brookline Capital Markets Reiterates Buy Rating, $19 Price Target on Caribou Biosciences (CRBU)
May 16, 2022 02:36PM Crown Electrokinetics (CRKN) PT Lowered to $1.50 at Dawson James on Financing Risk
May 16, 2022 02:29PM Chimerix (CMRX) PT Lowered to $10 at Cowen on Tembexa Sale and "More Challenging Than Expected" Path to Approval
May 16, 2022 09:49AM Cantor Fitzgerald Reiterates Overweight Rating. $15 Price Target on ContraFect (CFRX), "Expect Upwards Earnings Revision to Move Share Higher"
May 16, 2022 09:31AM "Concerned the Company Will Need to Raise Capital Again" - Kintara Therapeutics (KTRA) Downgraded to Neutral at Dawson James
May 16, 2022 08:14AM GVB Biopharma Acquisition "Adds Scale, Scope and Diversification" - Dawson James Bullish on 22nd Century Group (XXII) with $8.50 Price Target
May 16, 2022 05:31AM Truist Securities Reiterates Buy Rating, $50 Price Target on Marinus Pharmaceuticals (MRNS) Following Q1 Report, "Increasingly Bullish on TSC Indication for Oral GNX"
May 13, 2022 07:06AM Brickell Biotech Inc. (BBI) PT Lowered to $1 at Oppenheimer, But Analyst Reiterates Buy Rating on BBI-02 Potential
May 13, 2022 06:34AM Needham & Company Reiterates Buy Rating, $20 Price Target on CorMedix (CRMD) Ahead of DefenCath's 3Q22 PDUFA
May 13, 2022 06:32AM Synlogic Inc. (SYBX) PT Lowered to $6 at Oppenheimer on Pushed Back Guidance, but Analyst Continues to "See SYBX Shares as Bargain", Reiterate Outperform Rating
May 13, 2022 06:27AM Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 Price Target, Expects "Upwards Earnings Estimate Revisions and Multiple Expansion"
May 13, 2022 06:25AM Cantor Fitzgerald Reiterates Overweight Rating on Fortress Biotech (FBIO) on Q1 Report, "Risk-Diversification Remains Attractive "
May 13, 2022 06:24AM Stifel Reiterates Buy Rating on CTI BioPharma (CTIC) with $6.20 Price Target
May 13, 2022 06:22AM Needham & Company Reiterates Buy Rating, $8 Price Target on CTI BioPharma (CTIC) Following Q1 Report, "We Are Encouraged by Initial Strong Numbers"
May 13, 2022 06:19AM Cantor Fitzgerald Reiterates Overweight Rating on Checkpoint Therapeutics (CKPT) on Q1 Report
May 13, 2022 06:18AM Mirati Therapeutics (MRTX) PT Raised to $133 at Stifel, Sees Multiple Reason to "Lean Bullish" Despite Market Skepticism
May 13, 2022 06:16AM Oppenheimer Reiterates Outperform Rating, $16 Price Target on Milestone Pharmaceuticals (MIST), "We Like Risk/Reward into RAPID Trial Readout"
May 13, 2022 06:15AM Stifel Reiterates Buy Rating, $12 Price Target on Equillium (EQ) Ahead of Upcoming Data Readouts
May 13, 2022 06:14AM X4 Pharmaceuticals (XFOR) PT Lowered to $8 at Oppenheimer on Higher Q1 Loss, but Stays "Bullish on XFOR Ahead of Pivotal WHIM Data"
May 13, 2022 06:10AM Cantor Fitzgerald Reiterates Overweight Rating, $5 on PAVmed (PAVM), "Encourage Investors to Acquire PAVM Shares at Attractive Valuation"
May 13, 2022 06:07AM Oppenheimer Reiterates Outperform Rating, $6 Price Target on CASI Pharmaceuticals (CASI) Following Company's Q1 Update
May 13, 2022 06:05AM Stifel Reiterates Buy Rating, $35 Price Target on Kinnate Biopharma (KNTE) Ahead of the Upcoming KIN-2787 Readouts
May 13, 2022 06:04AM Oppenheimer Reiterates Outperform Rating, $17 Price Target on Alpine Immune Sciences (ALPN) Ahead of ALPN-303 First-in-Human Data
May 13, 2022 05:59AM Oppenheimer Reiterates Outperform Rating, $38 Price Target on Viridian Therapeutic (VRDN) Following the Company's Q1 Update
May 13, 2022 05:57AM Needham & Company Reiterates Buy Rating, $8 Price Target on Trevi Therapeutics (TRVI) Ahead of Upcoming Trial Data, "Focus Now Turns to The Ph 2b/3 PRISM Trial"
May 12, 2022 11:06AM Oppenheimer Reiterates Outperform Rating, $36 Price Target on Caribou Biosciences (CRBU), "Impressed with CB-010 Data"
View More Recent Stories View Older Stories